Mammalian Cell Fermentation Technology Market Size & Share, by Type (Chinese Hamster Ovary [CHO] Cell Fermentation, Human Embryonic Kidney [HEK] Cell Fermentation, Baby Hamster Kidney [BHK] Cell Fermentation); Application (Monoclonal Antibodies, Recombinant Proteins, Vaccines); End-Use (CMOs & CDMOs, Biopharmaceutical Companies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Growth Drivers

• Growth in Making of Personalized Medications - Recent years have seen a significant increase in the popularity of personalized medicine, due to the potential for less side effects and more successful therapies. The area of personalized medicine and mammalian cell fermentation technology combine in a profound and innovative way. Personalized medical's basic goal is to identify the optimal course of treatment for each individual patient. This usually means developing highly targeted therapeutics, including gene therapies, cell-based therapies, and monoclonal antibodies. The creation of these innovative medicines requires the fermentation of mammalian cells.
• Advancement in Technology for Mammalian Cell Fermentation - Mammalian cell fermentation is growing more effective and scalable due to ongoing advancements in cell culture methods, medium compositions, and bioreactor architecture. For instance, in case of bioreactors the utilization of single use bioreactors is growing. Most fermentation operations performed nowadays take place in bioreactors constructed from conventional materials including stainless steel. However, disposable technology is gaining popularity as a means to improve flexibility, and reducing batch change-over time. These systems are rapidly establishing themselves as another important technological advancement in the fields of pharmaceutical applications and mammalian cell culture. Furthermore, when single-use bioreactors with rigorous qualification and validation processes are used with very potent biopharmaceutical ingredients, the risk of cross-contamination is decreased and process safety is improved. As a result, the market is observing growth over the coming years.
• Rising Chronic Disease - According to the World Health Organization, noncommunicable diseases (NCDs) account for 41 million annual deaths worldwide, or 74% of all fatalities. The ability to regulate gene expression has been studied in mammalian cells, both in vitro and in vivo. It is possible to modify gene regulation in intact animals as well as in cultured cardiomyocytes, with potential applications in the management of chronic human illness. Hence, the demand for mammalian cell fermentation technology is projected to have significant growth.

Challenges

• High Cost of Capital - Mammalian cell fermentation technology is crucial to the biotechnology and pharmaceutical industries, however one major obstacle to its growth is the high capital costs associated with it. Smaller companies and startups often find it difficult to enter the mammalian cell fermentation industry due to the substantial financial investment required to create and operate these facilities. Furthermore, the primary driver of these capital costs is the need for specialized infrastructure. Mammalian cell fermentation usually takes place within large, complex tanks called bioreactors, which are designed to provide a controlled environment for cell growth and product synthesis. Temperature, pH, oxygenation, and agitation are just a few of the parameters that these bioreactors must meet carefully. Building and certifying these bioreactors to meet regulations would come at a high financial cost. Another aspect pushing up capital expenses is the need for highly skilled workers. Facilities for the fermentation of mammalian cells must be run and maintained by personnel skilled in cell culture techniques, bioprocess engineering, and regulatory compliance. The competitive salaries that these professionals command further increase the overall cost.
• Strict Regulatory Challenges
• Lack of Knowledge Regarding New Technology.